ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant Sacituzumab Govitecan + Pembro vs Pembro ± Capecitabine in TNBC and Residual Disease After Neoadjuvant Therapy and Surgery"

2,212 views
June 7, 2023
0 Comments
Login to view comments. Click here to Login